VIR BIOTECHNOLOGY INC's ticker is VIR and the CUSIP is 92764N102. A total of 229 filers reported holding VIR BIOTECHNOLOGY INC in Q1 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $796,581 | -57.3% | 85,014 | +11.7% | 0.00% | -60.0% |
| Q2 2023 | $1,867,592 | +18.8% | 76,135 | +12.7% | 0.01% | 0.0% |
| Q1 2023 | $1,572,517 | -15.1% | 67,577 | -7.7% | 0.01% | -16.7% |
| Q4 2022 | $1,852,591 | +30.1% | 73,196 | -0.9% | 0.01% | +20.0% |
| Q3 2022 | $1,424,000 | -22.7% | 73,871 | +2.2% | 0.01% | 0.0% |
| Q2 2022 | $1,842,000 | -29.2% | 72,304 | -28.6% | 0.01% | 0.0% |
| Q1 2022 | $2,603,000 | -29.8% | 101,200 | +14.2% | 0.01% | -28.6% |
| Q4 2021 | $3,710,000 | +8.9% | 88,600 | +13.2% | 0.01% | 0.0% |
| Q3 2021 | $3,408,000 | -9.1% | 78,300 | -1.3% | 0.01% | -12.5% |
| Q2 2021 | $3,749,000 | -7.0% | 79,300 | +0.9% | 0.01% | -11.1% |
| Q1 2021 | $4,030,000 | +99.3% | 78,600 | +4.1% | 0.01% | +80.0% |
| Q4 2020 | $2,022,000 | -20.7% | 75,500 | +1.6% | 0.01% | -16.7% |
| Q3 2020 | $2,551,000 | -16.2% | 74,300 | 0.0% | 0.01% | -25.0% |
| Q2 2020 | $3,044,000 | +701.1% | 74,300 | +569.4% | 0.01% | +700.0% |
| Q1 2020 | $380,000 | – | 11,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 22,616,666 | $284,405,000 | 3.12% |
| INDUS CAPITAL PARTNERS, LLC | 681,936 | $8,575,000 | 1.68% |
| Alphabet Inc. | 1,666,666 | $20,958,000 | 1.27% |
| Temasek Holdings (Private) Ltd | 5,499,999 | $69,162,000 | 0.45% |
| Board of Trustees of The Leland Stanford Junior University | 38,905 | $490,000 | 0.06% |
| Baillie Gifford | 500,000 | $6,287,000 | 0.01% |
| Marshall Wace North America L.P. | 74,898 | $941,000 | 0.01% |
| Capital International Investors | 983,300 | $12,365,000 | 0.00% |
| Blackstone Inc. | 35,000 | $440,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,908 | $24,000 | 0.00% |